SUNNYVALE, Calif., Sept. 17, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announces that The Lancet Oncology, a high impact and leading global peer-reviewed oncology journal, has published patient- and clinician-reported outcomes data from the PACE — Prostate Advances in Comparative Evidence — trial in its most recent issue. While furt

SAN DIEGO, Sept. 17, 2019 /PRNewswire/ -- Abcentra, a clinical-stage bio-pharmaceutical company that addresses unmet needs in inflammation, today announced its contribution to a 2019 study published in the American Heart Association Journals. The study found that, in those with high-cholesterol and major histocompatibility complex class II (MHCII) cells, treating at

Achieves first positive Adjusted EBITDA1 quarter of $3.2 million. Q4 2019 net revenue was $19 million, a 90% increase from Q3 2019 ($10 million). Fiscal 2019 total revenue was $41.8 million, a 370% increase from fiscal 2018 ($8.9 million).

BRAINTREE, Mass., Sept. 17, 2019 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2020 financial results at 6:00 am EDT on Friday, November 1, 2019. The Company will hold a conference call with investors and analysts to discuss results and answer questions at

DUBLIN, Sept. 17, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY J

SAN DIEGO, Sept.17, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses from its movement disorder programs, including INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD); opicapone, an investigational adjunctive treatment for Parkin

FREMONT, Calif., Sept. 17, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a compa

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or the "Company") (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced the closing of the Company's previously announced initial public offering o

SOUTH PLAINFIELD, N.J., Sept. 17, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing an offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"), subject to market conditions and other factors. The Notes are to be offered and so

SOUTH PLAINFIELD, N.J., Sept. 17, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of $100.0 million of shares of its common stock. PTC intends to grant the underwriter an option for a period of 30 days to purchase up to an additional $15.0 million